NCT06577259

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

A Phase 1, Open-label, Single-site, Randomized, Single-dose, Three-way, Crossover Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	BMS-986435	Specified dose on specified days

Timeline

• Start date: 2024-09-03
• Primary completion: 2025-02-19
• Completion: 2025-02-19
• First posted: 2024-08-29
• Last updated: 2025-03-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study